Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Masato Tobinai"'
Autor:
Toshitaka Nakamura, Junko Hashimoto, Seitaro Yoshida, Masao Yamamoto, Masato Tobinai, Tetsuo Nakano
Publikováno v:
Journal of Bone and Mineral Metabolism. 34:678-684
We examined response to bone mineral density (BMD) gains in the MOVER study following treatment with intravenous (IV) ibandronate 1 mg/month, and investigated the characteristics of a non-responder group. At 1 year, responder rates for patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ce8c7eea2adf1f9f1b63421179ebb3
https://doi.org/10.1007/s00774-015-0717-8
https://doi.org/10.1007/s00774-015-0717-8
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Ibandronate is a drug widely used outside Japan for the treatment of osteoporosis. It is available in formulations for intermittent intravenous (i.v.) administration and for intermittent (once monthly) oral administration. Ibandronate was recently ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1fd007e97c6ba5f8946ea31f137cea
https://doi.org/10.1007/s13318-014-0242-5
https://doi.org/10.1007/s13318-014-0242-5
Publikováno v:
Journal of bone and mineral metabolism. 35(1)
We examined the efficacy of intravenous (IV) ibandronate 1 mg/month in patient subgroups in the phase III MOVER study. Here we present results of analyses on the incidence of fractures in patients with prevalent vertebral fractures (1 or ≥2, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29beb4c2826652952cb7a390fa4feafc
https://pubmed.ncbi.nlm.nih.gov/26614597
https://pubmed.ncbi.nlm.nih.gov/26614597
Publikováno v:
Clinical pharmacokinetics. 54(3)
Ibandronate, a nitrogen-containing bisphosphonate, is a bone resorption inhibitor widely used to prevent and treat osteoporosis. To optimize the design for a long-term clinical study of ibandronate, modeling and simulation (MS) was performed based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9533ecefaef94b3c6f620e8e74a3e893
https://pubmed.ncbi.nlm.nih.gov/25791897
https://pubmed.ncbi.nlm.nih.gov/25791897
Autor:
Masato, Tobinai
Publikováno v:
Clinical calcium. 21(1)
Ibandronate is a potent nitrogen-containing bisphosphonate and is a convenient therapeutic drug for osteoporosis because ibandronate can be administrated once a month or at much longer interval by orally or intravenously (bolus injection). In BONE st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::46e8936143bdde734a312d029fd16f57
https://pubmed.ncbi.nlm.nih.gov/21187598
https://pubmed.ncbi.nlm.nih.gov/21187598
Publikováno v:
Clinical Pharmacokinetics. 54:455-455
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::993772b844a0f95d2e65a6f557f09164
https://doi.org/10.1007/s40262-015-0263-5
https://doi.org/10.1007/s40262-015-0263-5
Autor:
Masato Tobinai, Masayuki Matsunaga, Toshitaka Nakamura, Seitaro Yoshida, Junko Hashimoto, Hiroshi Hagino
Publikováno v:
Calcified Tissue International
The relationship between gains in bone mineral density (BMD) in the hip and the incidence of vertebral fractures in the MOVER study was examined. Japanese patients from the ibandronate and risedronate treatment groups whose hip BMD had increased duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cbac992c4bb98f1095d4d4a65d7ae7